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Abstract
Background: Concomitant infections may influence HIV progression by causing chronic activation leading to
decline in T-cell function. In the Americas, visceral (AVL) and tegumentary leishmaniasis (ATL) have emerged as
important opportunistic infections in HIV-AIDS patients and both of those diseases have been implicated as
potentially important co-factors in disease progression. We investigated whether leishmaniasis increases
lymphocyte activation in HIV-1 co-infected patients. This might contribute to impaired cellular immune function.
Methods: To address this issue we analyzed CD4
+ T absolute counts and the proportion of CD8
+ T cells
expressing CD38 in Leishmania/HIV co-infected patients that recovered after anti-leishmanial therapy.
Results: We found that, despite clinical remission of leishmaniasis, AVL co-infected patients presented a more
severe immunossupression as suggested by CD4
+ T cell counts under 200 cells/mm
3, differing from ATL/HIV-AIDS
cases that tends to show higher lymphocytes levels (over 350 cells/mm
3). Furthermore, five out of nine, AVL/HIV-
AIDS presented low CD4
+ T cell counts in spite of low or undetectable viral load. Expression of CD38 on CD8
+ T
lymphocytes was significantly higher in AVL or ATL/HIV-AIDS cases compared to HIV/AIDS patients without
leishmaniasis or healthy subjects.
Conclusions: Leishmania infection can increase the degree of immune system activation in individuals
concomitantly infected with HIV. In addition, AVL/HIV-AIDS patients can present low CD4
+ T cell counts and higher
proportion of activated T lymphocytes even when HIV viral load is suppressed under HAART. This fact can cause a
misinterpretation of these laboratorial markers in co-infected patients.
Background
Leishmania/HIV-1 co-infection has been considered an
emerging disease mainly due to the expansion of the
AIDS epidemic over leishmaniasis endemic areas and
vice-versa [1]. Visceral leishmaniasis associated-HIV/
AIDS is well known as an opportunistic disease espe-
cially in the Mediterranean basin [1]. However, an
increasing number of reports of tegumentary leishma-
niasis-HIV/AIDS patients underlines the importance of
this additional association [2-6]. In America, vector
sandflies and Leishmania species that cause American
visceral leishmaniasis (AVL) and tegumentary leishma-
niasis (ATL) differ from those observed in other ende-
mic regions around the world. This could result in the
particular clinical features observed in HIV-co-infected
patients in the New World [3,7]. In Brazil, both Leish-
mania and HIV infection are endemic and this co-infec-
tion is becoming an important public health problem
[1,7].
The clinical outcome of both AVL and ATL is depen-
dent on the Leishmania-specific immune response. This
influence can be exerted in many different ways. AVL is
a systemic infection affecting lymphoid organs; it is
associated with parasite antigens driving an impaired
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as well as systemic CD4
+ and CD8
+ T lymphocytes. Pro-
found immunosuppression is the consequence [8-11]. In
contrast, ATL is a benign disease which affects skin and
mucous membranes. In these ATL patients, the specific
immune response is preserved though not well regu-
lated, leading to tissue damage [10,12]. Even considering
the differences in the clinical and immunopathogenesis
of those AVL and ATL, T lymphocyte function is
affected in both diseases, and the clinical cure is
achieved by restoration of an adequate effector immune
response [9-12].
Earlier studies have shown that Leishmania infection
can promote HIV-1 replication in vitro [13] and in vivo
[14]. Beside this, HIV-1 infection impairs macrophage
ability to control intracellular protozoans, enabling
Leishmania growth [15,16]. While highly effective anti-
retroviral therapy (HAART) has been shown to decrease
significantly the incidence of leishmaniasis in HIV-
infected patients [17,18], it does not seem to prevent
relapses [19]. This suggests that maintenance of the
parasite can impact the pathogenesis of both diseases.
Low lymphocyte recall responses after parasite stimula-
tion but preserved IFN-g production in ATL-HIV-AIDS
patients were already demonstrated [3]. On the other
hand, high type 2 cytokines levels are observed in HIV/
AIDS associated AVL, potentially favoring the dissemina-
tion of both the virus and Leishmania [14]. Moreover,
increased levels of CCR5 molecules on CD3
+ lympho-
cytes were also observed in AVL/HIV-AIDS [20], sug-
gesting that Leishmania infection could favor HIV-1
entry into its target cells through this receptor. Immuno-
logical studies reporting Leishmania/HIV co-infection
generally involve patients with active disease [3,14,20,21],
but the mechanisms that maintain leishmaniasis in
remission, and by consequence the factors that predis-
pose the parasite reactivation are poorly understood.
Chronic activation of the immune system has been
considered an important mechanism related to declining
lymphocytic functions and has become an important
tool for monitoring HIV-1 infected patients [22]. The
proportion of CD8
+ T cells that express CD38
+, a surro-
gate of activation marker, can predict the subsequent
decline of the CD4
+ T cell population [23] and was cor-
related with high viral load levels in HIV infected indivi-
duals [24]. Actually, the degree of cellular activation,
evidenced by the co-expression of CD38 and HLA-DR
on T lymphocytes has been considered an important
predictor of disease progression [25]. Concomitant
infections can exert an impact on viral replication by
contributing to an increase in T lymphocyte activation
already seen in HIV patients [26]. In accordance with
this, co-infection with HIV and tuberculosis results in
high levels of CD38 on CD8
+ T cells [27]. Nevertheless,
viral infections concomitant with HIV-1 infection seem
to have different effects on T lymphocyte activation.
Recent evidence showed that Hepatitis C virus/HIV-1
co-infected patients presented elevated immune activa-
tion levels, despite effective antiretroviral therapy [28].
On the other hand, GB virus type C replication has
been associated to lower T cell activation, which has
considered a protective mechanism involved in the HIV-
1 disease progression [29]. No influence of human her-
pesvirus replication on cell activation has been observed
[30]. However, the impact of Leishmania infection on
T cell perturbation due to HIV-1 is still unclear.” We
hypothesized that Leishmania infection could be an
additional factor for lymphocyte activation and lead to
impaired effect or immune function, favoring parasite
replication and, consequently, frequent relapses. There-
fore, we investigated whether leishmaniasis could impact
T lymphocytes activation in HIV-1 co-infected patients
through the analysis of CD4
+ T absolute counts and of
the proportion of CD8
+ T cells expressing CD38 in
Leishmania/HIV co-infected patients recovered after
anti-leishmanial therapy.
Methods
Patients and Subjects
Seventeen HIV-Leishmania co-infected patients (AVL-
HIV/AIDS - 9 cases and ATL-HIV/AIDS - 8 cases)
were enrolled for this study. Patients were in the remis-
sion phase, minimum six months after the end of their
anti-Leishmania treatment and had no signs or symp-
toms of active leishmaniasis (Table 1). Sixteen HIV-1/
AIDS cases, without previous leishmaniasis paired with
co-infected patients by viral load (HIV RNA copies/mL:
< 400, > 400 to 10.000 and over > 10,000 copies/mL)
and eight healthy volunteersw e r ei n c l u d e da sc o n t r o l s .
HIV/AIDS patients were receiving antiretroviral therapy
for at least one year, according to the Brazilian guide-
lines. Informed consent was obtained from all partici-
pants. The study was approved by the Fundação
Oswaldo Cruz and IPEC Ethical Committees.
Immunologic and virologic assessments
To determinate the absolute counts of CD4
+ T and CD8
+ T lymphocytes, a BD Tritest® monoclonal antibody
specific for CD4/CD8/CD3 conjugated to FITC, PE and
PerCP, respectively and BDTrue Count® reagent kit was
used according to the manufacturer’s instructions (BD
Biosciences, Franklin Lakes, NJ, USA). Samples were
acquired using a FACSCalibur® (BD, USA) and analysed
by Multiset® software (BD, USA). Plasma HIV-1 RNA
levels were quantified using the branched DNA assays
(Siemens, Versant HIV-1 RNA 3.0, Tarrytown, NY,
USA). The lower limit of detection for this assay was
50 copies/mL.
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(PBMC) and immune activation
PBMC were separated by centrifugation over a gradient
of Ficoll-Hypaque (Histopaque 1077; Sigma Chemical
Company, St. Louis, MO, USA) and ressuspended in
phosphate-buffered saline (PBS) containing 0,1% of
sodium azide (Sigma, USA). PBMCs were adjusted to10
5
cells and labeled with anti-CD8 FITC plus anti-CD38
PE monoclonal antibodies (BD Simultest™,B DB i o s -
ciences, San Jose, CA, USA). After incubation, the cells
were fixed with PBS plus 1% paraformaldehyde. At least
10,000 events were acquired using a FACSCalibur and
phenotypic analysis was carried out by using Cell-
Quest™software (BD). Although the validated marker of
CD8
+T cell activation is the co-expression of CD38 and
HLA DR, we used the detection of CD38 in CD8
+ as a
surrogate of this validated marker [25]. CD38 positivity
was determined on CD8
+ T cell populations inside the
gate previously established for TCD3
+ and expressed as
a percentage of CD38 in CD8
high.
Statistical analysis
The values were expressed as medians and interquartile
range. Statistical analysis was performed using the
Mann-Whitney U test (GraphPad Prism, version 4.0,
San Diego, CA, USA). Multivariate linear regression
analysis (SPSS software, version 9.0) was used to deter-
mine influence that of intervenient factors on the per-
centage of CD8
+ T cells expressing CD38 (dependent
variable). Absolute counts of CD4
+ T cells, viral load
(undetectable or detectable) and Leishmania infection
(presence or absence) were considered as independent
variables. Statistically significant differences were consid-
ered when p < 0.05.
Results
Clinical and laboratory characteristics are depicted in
Table 1 and 2. AVL-HIV/AIDS patients in clinical
remission showed significantly (p < 0.001) lower num-
bers of CD4
+ T lymphocytes in comparison to HIV-1
infected patients without leishmaniasis, (Figure 1A and
Table 1). In contrast, CD4
+ T counts in ATL-HIV/AIDS
patients were similar to HIV-1 infected patients without
leishmaniasis (Figure 1A). Both types of co-infected
patients and the HIV-1 infected patients without leish-
maniasis had much lower levels of CD4
+ T counts when
compared to healthy donors (p < 0.001, Figure 1A).
HIV-1 viral load in AVL/HIV-AIDS was not corre-
lated with CD4
+ T cell count, since low or undetectable
levels of HIV-1 were seen even in patients with very low
CD4
+ T cells counts (Figure 1B). By contrast, ATL/HIV-
AIDS patients in clinical remission had higher CD4
+ T
cell numbers and exhibited the lowest HIV plasma viral
load (Figure 1B).
HIV-1 co-infected individuals (AVL and ATL), had a
significantly higher percentage of CD8
+ T cells that
expressed CD38 when compared to HIV-1 infected
patients without leishmaniasis (median 55.8%; [49% -
64%], p < 0.05) (Figure 1C). However, the frequency of
CD38 expressed by the CD8
+ T cell subset was much
higher in AVL/HIV-AIDS cases (median 93.5%, [87%-
97.9%]) than in patients with ATL/HIV-AIDS (median
77%, [69%-83.6%], p < 0.001). Healthy blood donors
showed the lowest levels of CD8
+ T cell activation
(CD38
+ on CD8
+ T cells = median 31.2%; [24%-35.6%],
p < 0.001) (Figure 1C). There was no correlation
between the percentages of CD38 on CD8
+ Tc e l la n d
plasma HIV-1 viral load (Table 3), since high levels of
activation were observed despite viral load levels in the
co-infected patients (Figure 1D). HIV-1 infected controls
presented a positive correlation between the viral load
and cellular activation (p = 0.01, r = 0.60, data not
show).
A multivariate statistical analysis showed a significant
positive correlation between Leishmania infection and
the levels of CD38 on CD38 T lymphocytes (p < 0.001),
Table 1 Clinical and laboratorial characteristics of HIV-1 co-infected leishmaniasis patients and control groups
Parameters AVL/HIV-1 patients
(n = 9)
ATL/HIV-1 patients
(n = 8)
HIV-1
infected*
(n = 16)
Healthy subjects
(n = 8)
Age, years, (median) 38 (35-50)
a 44 (38-54)
b 39 (33-49)
c 26 (25-30)
abc
Male sex, n, (%) 9 (100)
d 8 (100)
e 15 (94)
f 4 (50)
def
CD4
+T Cell count, cells/mm
3 62 (52-127)
g 404 (294-597)
h 380 (223-450)
i 1,106 (957-1,300)
ghi
Current AIDS diagnosis, Number of cases (%) 9 (100) 6 (75) 8 (50) ——
Time of clinical remission of leishmaniasis, months 8 (6-12) 11 (7.5-14) —— ——
Patients with undetectable viremia, (%) 5 (55.6) 4 (50) 9 (56.2) ——
Viral load levels of patients with
detectable viremia, copies/mL
142,240 (24,025-279,321) 6,200 (2,012-78,176) 12,010 (2,000-136,625) ——
N = number, AVL - American visceral leishmaniasis, ATL - American tegumentary leishmaniasis *HIV-1 infected patients without leishmaniasis Note: Data are
median (interquartile range) values, except for current AIDS diagnosis.
Patients × Health subjects (a - p < 0.001; b/c - p < 0.01; d/e/f × def - p < 0.05), g/h/i × ghi - p < 0.001; g × h - p < 0.01; g × i - p < 0.01.
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+ T counts and HIV viremia
(Table 3). A covariance was not performed because of
the low number of ATL and AVL patients.
Discussion
Leishmania can persist in the host after treatment and
may further reactivate under immunossupression [1]. A
host parasite dynamic equilibrium does not seem to be
reached in HIV co-infected patients probably because
immunosupressed patients are not able to mount an
efficient T-cell response to control Leishmania, resulting
in frequent relapses especially in AVL but also in ATL
[1,5]. We found that despite clinical remission of proto-
zoan disease, AVL co-infected patients were more
severely immunossupressed than ATL co-infected
patients. Furthermore, lymphocyte activation status was
higher in both groups of co-infected patients than in
HIV-1-infected patients without leishmaniasis. Our
results suggest that Leishmania infection increases the
degree of the immune system activation in individuals
concomitantly infected with HIV-1. This phenomena
Table 2 CD4+ T cell counts and viral load levels of HIV-
AIDS associated leishmaniasis patients (visceral or
tegumentary) and HIV-1 infected control group
Patient’s
Number
CD4
+ T cells counts(cells/
mm
3)
Viral load levels
(copies/mL)
VL/HIV-AIDS
1 78 < 400
2 59 5,810
3 33 316,402
4 129 < 400
5 61 < 400
6 45 242,240
7 187 < 400
8 124 42,240
9 68 < 400
TL/HIV-AIDS
1 367 1,700
2 440 < 400
3 512 2,324
4 86 146,351
5 541 < 400
6 345 < 400
7 576 < 400
8 242 10,000
HIV-1 infected
1 146 136,625
2 543 < 400
3 215 < 400
4 34 12,010
5 230 253,761
6 609 < 400
7 391 < 400
8 491 < 400
9 377 < 400
10 73 1,750
11 371 10,000
12 236 < 400
13 635 < 400
14 382 2,000
15 394 55,239
16 410 < 400
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Figure 1 Relationship between lymphocyte immune status and
plasmatic HIV-1 viral load in Leishmania/HIV-1 co-infected
patients during remission phase of leishmaniasis. A. Absolute
counts of CD4
+ T lymphocytes. B. Absolute counts of CD4
+ T
lymphocytes and viral load levels. C. Levels of CD38 expression on
CD8
+ T lymphocytes. D. CD38 expression on CD8
+ T lymphocytes
and viral load levels. American visceral leishmaniasis (AVL)/HIV-AIDS
patients (solid squares), American tegumentary leishmaniasis (ATL)/
HIV-AIDS patients (solid triangles), HIV-1 infected adults without
leishmaniasis (HIV infected, solid diamonds) and healthy subjects
(solid circles). Each point represents one subject. The horizontal bars
express median.
Table 3 Multivariate linear regression analysis to
evaluate the association between T cell activation (CD38
+ on CD8+ T lymphocytes) and independent variables in
leishmaniasis and HIV-1 co-infected patients
Independent variables Dependent variable
Percentage of CD38
+ on CD8
+ T
lymphocytes
Coef
1 SE
2 P
Leishmania infection
(presence or absence)
24.88 4.63 0.000011
CD4
+ T cell count, cells/mm
3 -0.02 0.013 0.13
Viral load levels
(detectable or undetectable)
4.12 4.85 0.39
1 Coef - Correlation coefficient, 2 SE - Standard error
Obs. HIV-1 infected patients were also included in this analysis.
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an additional mechanism for explain relapses.
Both AVL and ATL tend to emerge as opportunistic
diseases in HIV infected patients without leishmaniasis
especially in those presenting with CD4
+ T cell levels
below 350 cells/mm
3 [1,4,5,31,32]. In this study, AVL/
HIV-AIDS patients presented very low CD4
+ T cell levels
during remission of clinical symptoms after successful
anti-leishmanial therapy and under HAART use. This
was not observed in ATL/HIV-AIDS. The low CD4
+ T
cell counts observed in AVL co-infected patients cannot
be solely explained by lymphocyte depletion related to
HIV-1 replication, since low CD4
+ Tc e l lc o u n t sw e r e
observed in AVL/HIV-AIDS patients with undetectable
or low viral load levels. Additionally, CD4 T cell deple-
tion of bone marrow caused by both HIV infection [33]
and AVL [9,11] was already demonstrated and may lead
to deficiencies in the input of new lymphocytes into the
periphery. These factors could explain why AVL/HIV-
AIDS patients already had CD4 cell counts lower than
200 cells/mm
3 at the beginning of anti-leishmanial ther-
apy (data not shown), which additionally could contri-
bute to the maintenance of low levels during remission
phase. By contrast, the immunopathogenesis of ATL/
HIV-AIDS may not be related to systemic imunossup-
pression since ATL is more restricted to the tegument
and the draining lymph nodes. In this connection, these
ATL/HIV-AIDS patients in remission phase apparently
recovered their lymphocyte levels (data not shown) since
they have much higher CD4
+ T cell counts than those
previously observed in patients with active disease [3-5].
In the present study we have shown that leishmaniasis/
HIV-AIDS patients displayed elevated levels of CD38 on
CD8
+ T cells levels in relation to HIV-1 infected patients
without leishmaniasis. This implies that concomitant
Leishmania infection could contribute to enhance the acti-
vation induced by HIV antigens as has been described in
tuberculosis [27] and hepatitis C virus [28]. The finding of
high CD38 levels positively correlated with Leishmania
infection reinforces the idea that leishmaniasis can be a
cofactor to of this heightened activation status. It is known
that high activation levels are inversely proportional to the
CD4
+ T cell levels, suggesting that activation could also
contribute to the T cell depletion [22,25,34]. Interestingly,
CD38 levels observed in co-infected patients were much
higher than those seen in cured AVL and ATL patients
without HIV/AIDS (unpublished data). This result raises
the possibility that parasite persistence might have a role
in this activation process, since released Leishmania anti-
gens can stimulate lymphocytes. The frequent relapses
described in AVL/HIV-AIDS, which occur more frequently
than in ATL/HIV-AIDS patients, could be evidence of this
reduced ability to maintain the parasite under control due
to the impaired immune function [4,19]. Viscerotropic
Leishmania species in the bone marrow promote immuno-
logical damage to a greater extent than dermotropic para-
sites do in the skin [4,11].
This could be, at least in part, why activation levels
were higher in AVL/HIV-AIDS than in ATL/HIV-AIDS
patients.
Conclusion
Taken together, our results point to co-infection with
leishmaniasis as a factor that is likely to increase the sever-
ity of immunodeficiency caused by HIV, especially in
AVL/HIV-AIDS patients. The low T CD4 cell counts
among those patients with AVL/HIV-AIDS after remis-
sion, even in the absence of detectable viral load may have
important implications for the HAART monitoring.
Furthermore, the prognostic value of CD38 expression on
CD8
+ T cells might not be useful in predicting HIV-1 pro-
gression in co-infected patients [35] since these molecules
levels stay elevated after clinical remission of leishmaniasis.
To our knowledge no previous study has evaluated the
degree of immune activation in Leishmania/HIV-1 co-
infected patients. Further studies evaluating the conse-
quences of high levels of cellular activation will be of great
interest as immunological abnormalities in T lymphocyte
function can impact the clinical course of both infections.
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